The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
A Personalized Medicine Coalition-funded study has found that NGS-based testing is moderately cost effective but that access to targeted treatments remains a hurdle.
Regulators in the country granted additional approval of the test as a companion diagnostic for Rozlytrek, marketed in Japan by Roche's Chugai Pharmaceutical.
Among Kiromic's platforms is an artificial intelligence product that combines genomic sequencing, proteomic, and clinical data to provide predictive algorithms.
